BioFactura

BioFactura is a private, clinical-stage biotech company with a diversified portfolio spanning biosimilars, biodefense, and novel therapeutics. Its core asset is the patented StableFast™ Biomanufacturing Platform, designed to produce biologics faster, with higher yields, and at lower cost. The company generates revenue through government contracts and grants, particularly for biodefense programs, and has recently launched a CDMO division, Capitol Biologics, to expand its service offerings. With a pipeline featuring both internal and partnered programs in various stages of development, BioFactura operates at the intersection of commercial healthcare and government-funded biodefense.

Proprietary StableFast™ Biomanufacturing Platform, a system using NS0 and CHO cell lines to rapidly generate stable, high-yielding cell lines for biologic production, claiming 3x faster production and 5x better yields.

In biosimilars, BioFactura competes with large generics firms (e.g., Sandoz, Viatris) and dedicated biosimilar companies, where cost and speed of development are critical. In biodefense, competitors include other government contractors like Emergent BioSolutions, Ology Bioservices, and SIGA Technologies. The new CDMO division enters a market dominated by large players like Lonza, Catalent, and Samsung Biologics, as well as numerous smaller, specialized CMOs.